Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks - Weinstein, Gerald D.; Koo, John Y.M.; Krueger, Gerald G.; Lebwohl, Mark G.; Lowe, Nicholas J.; Menter, M.Alan; Lew-Kaya, Deborah A.; Sefton, John; Gibson, John R.; Walker, Patricia S. (Journal of the American Academy of Dermatology, 2003)
Keywords: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Dermatologic Agents - administration & dosage; Dermatologic Agents - adverse effects; Dermatologic Agents - pharmacology; Dermatology; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Medical sciences; Middle Aged; Nicotinic Acids - administration & dosage; Nicotinic Acids - adverse effects; Nicotinic Acids - pharmacology; Pharmacology. Drug treatments; Psoriasis - drug therapy; Psoriasis - pathology; Psoriasis. Parapsoriasis. Lichen; Severity of Illness Index; Skin, nail, hair, dermoskeleton; Treatment Outcome; Human; Local administration; Skin disease; Chemotherapy; Treatment; Psoriasis; Tazarotene; Toxicity; Retinoid; Double blind study; Comparative study; Percutaneous route